CHMP recommends EU approval of Roche´s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC
(WorldNews Switzerland)

Basel, 13 October 2017 CHMP recommends EU approval of Roche`s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC Positive opinion based on phase III results showing Alecensa reduced the risk of disease progression or death by more than half versus crizotinib Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Union`s (EU) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Alecensa® (alectinib) as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). It has also simultaneously...